Microcap Ledger Nanoviricides, Inc. $NNVC
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- NYSE American
- Sector
- Pharmaceutical Preparations
- Headquarters
- Shelton, CT
- Fiscal year end
- June 30
- Shares outstanding
- 25,525,000 [10-K 2026-09-28]
What the company doesAI summary of filing
NanoViricides, Inc. is a clinical-stage company developing antiviral drugs based on nanoviricide platform technology that uses nanomicelles with ligands designed to mimic host cell attachment receptors. The company's lead candidate, NV-387, is a broad-spectrum antiviral with completed Phase I safety trials and ongoing Phase II trials for Mpox and Ebola in the Democratic Republic of Congo, with additional Phase II trials planned for measles and respiratory viral infections. The company has no revenues to date and manufactures drug substances and formulations at its own cGMP-compliant facility in Shelton, Connecticut. NanoViricides holds exclusive worldwide licenses from TheraCour Pharma for antiviral treatments across multiple viral disease fields including HIV, hepatitis, herpes, influenza, dengue, and Ebola, with royalty and milestone payment obligations to TheraCour. [10-K 2026-09-28]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| FY ended Jun 2026 | $0.00 | −$8.22M | −$7.70M | $2.79M | [10-K 2026-09-28] |
| FY ended Jun 2025 | $0.00 | −$9.47M | −$8.48M | $1.56M | [10-K 2025-09-29] |
- Quarterly cash burn
- −$1.92M
- Cash runway Estimate
- ~4.4 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-14 | 14,347,000 | [10-Q 2024-11-14] |
| 2025-02-14 | 15,641,000 | [10-Q 2025-02-14] |
| 2025-05-15 | 16,072,000 | [10-Q 2025-05-15] |
| 2025-09-27 | 17,431,000 | [10-K 2025-09-29] |
| 2025-11-14 | 17,997,000 | [10-Q 2025-11-14] |
| 2026-02-17 | 21,595,000 | [10-Q 2026-02-17] |
| 2026-05-14 | 21,647,000 | [10-Q 2026-05-15] |
| 2026-09-28 | 25,525,000 | [10-K 2026-09-28] |
- Shelf registration
- S-3 filed 2026-08-21; declared effective 2026-08-31 [S-3 2026-08-21]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-08 | DEF 14A | Proxy statement |
| 2026-09-29 | 8-K | Director or officer change |
| 2026-09-28 | 10-K | Annual report |
| 2026-09-03 | 424B3 | Prospectus or prospectus supplement |
| 2026-08-21 | S-3 | Registration statement |
| 2026-07-30 | 8-K | Material agreement entered; Other events |
| 2026-07-27 | 424B5 | Prospectus or prospectus supplement |
| 2026-07-27 | 424B5 | Prospectus or prospectus supplement |
| 2026-07-17 | 8-K | Material agreement entered |
| 2026-07-17 | 424B5 | Prospectus or prospectus supplement |
| 2026-07-01 | 424B3 | Prospectus or prospectus supplement |
| 2026-06-15 | S-3 | Registration statement |
Alerts for $NNVC
Email me when Nanoviricides, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.